Paper Details

  1. Home
  2. Paper Details

Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.

Author: ConnorKathryn M, HerringW Joseph, LinesChristopher, MichelsonDavid, MorinCharles M, SnavelyDuane B, SnyderEllen

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Suvorexant improved sleep quality and reduced the impact of insomnia on daytime function in patients with insomnia, as measured by the Insomnia Severity Index.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Suvorexant is an orexin receptor antagonist that is approved in the US, Japan and Australia for the treatment of insomnia. Using outcomes from the Insomnia Severity Index (ISI) in the core registration studies, we explored suvorexant effects on sleep problems and their impact on daytime f...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.sleep.2018.09.010

データ提供：米国国立医学図書館（NLM）

Effects of Suvorexant on Insomnia Severity Index in Patients with Insomnia

The desert of sleep disorders is a vast and challenging landscape, where researchers constantly seek to understand the mechanisms of insomnia and develop effective treatments. This study explores the effects of suvorexant, an orexin receptor antagonist, on patients with insomnia, using the Insomnia Severity Index (ISI) to assess the impact of treatment on sleep quality and daytime function.

Suvorexant: A Promising Treatment for Insomnia

The study's findings, like a refreshing oasis in the desert of sleep disorders, reveal the potential benefits of suvorexant for treating insomnia. The researchers found that suvorexant significantly improved ISI scores, indicating improved sleep quality and reduced daytime impairment. This research offers a promising path towards improving the lives of individuals struggling with insomnia.

Navigating the Desert of Sleep

This research, like a guidepost in the desert of sleep disorders, highlights the importance of developing effective treatments for insomnia. The study's findings provide valuable data for understanding the efficacy of suvorexant and its potential to improve sleep quality and daytime function, offering a beacon of hope for individuals seeking relief from insomnia.

Dr. Camel's Conclusion

This study, like a well-stocked caravan traversing a challenging desert, offers a valuable tool for managing insomnia. The findings demonstrate the potential of suvorexant to improve sleep quality and daytime function, providing a promising path towards achieving a restful night's sleep.

Date :
  1. Date Completed 2020-05-08
  2. Date Revised 2020-05-08
Further Info :

Pubmed ID

30522875

DOI: Digital Object Identifier

10.1016/j.sleep.2018.09.010

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.